Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02005315 · ClinicalTrials.gov registry record · Phase 1
A Study of Vantictumab (OMP-18R5) in Combination With Nab-Paclitaxel and Gemcitabine in Previously Untreated Stage IV Pancreatic Cancer
A Phase 1 study, sponsored by OncoMed Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
NCT02005315 is a Phase 1 study that has completed, run by OncoMed Pharmaceuticals. The registered enrollment target is 30 participants.
The verdict
NCT02005315, a Phase 1 study, has completed, sponsored by OncoMed Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
Study Summary
This is an open-label Phase 1b dose-escalation study to assess the safety, tolerability, and PK of vantictumab when combined with nab-paclitaxel and gemcitabine.
Interventions
- DRUG Nab-Paclitaxel
- DRUG Gemcitabine
- DRUG Vantictumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2013-09 |
| Est. Completion | 2017-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02005315
The ClinicalTrials.gov registry entry for NCT02005315 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is OncoMed Pharmaceuticals, which has 25 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Nab-Paclitaxel is the first listed.
NCT02005315 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02005315 about?
NCT02005315 is a clinical study titled "A Study of Vantictumab (OMP-18R5) in Combination With Nab-Paclitaxel and Gemcitabine in Previously Untreated Stage IV Pancreatic Cancer". This is an open-label Phase 1b dose-escalation study to assess the safety, tolerability, and PK of vantictumab when combined with nab-paclitaxel and gemcitabine.
What is the current status of trial NCT02005315?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2013-09. Estimated completion is 2017-11.
What interventions are being tested in trial NCT02005315?
The interventions under investigation include: Nab-Paclitaxel (DRUG), Gemcitabine (DRUG), Vantictumab (DRUG).
Who is sponsoring clinical trial NCT02005315?
This trial is sponsored by OncoMed Pharmaceuticals, which has 25 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.